In 301 prostate cancer patients without hormonal treatment, we analysed the impact on the biochemical response (bNED) to SRT of two pre-SRT PSA levels, namely below or above the median of 0.28 ng/ml.
The median follow-up time for the entire group was 30 months. In 151 patients, SRT commenced at a PSA 猢?.28 ng/ml, in 150 at >0.28 ng/ml. Eighty-two patients (27%) developed biochemical progression during follow up. The calculated two-year bNED was 74%for the entire group, 78%versus 61%for a PSA 猢?#xA0;or >0.28 ng/ml, respectively. In multivariate analysis, pT3b, resection status, pre-SRT PSA dichotomized at median, PSA post-SRT undetectable, and PSA doubling time were statistically significant independent predictors of progression after SRT.
Our findings suggest that a PSA of 猢?.28 ng/ml improves bNED compared with a PSA before SRT of >0.28 ng/ml.